DexCom (DXCM) said Friday it has set new long-term financial goals, including organic revenue growth of more than 10% a year through 2030.
Among the targets, initially disclosed at the company's investor day event on Thursday, are a 2030 non-GAAP gross profit margin of 67% to 69%, as well as a 2030 non-GAAP operating profit margin of 29% to 30%, DexCom said.
The company expects adjusted earnings before interest, taxes, depreciation, and amortization, or EBITDA, margin of 36% to 37% in 2030.
DexCom also said its board has approved a share buyback program of up to $1 billion, with a repurchase period ending no later than June 30, 2027.
The board terminated an existing share buyback plan, of which $250 million were available, the company said.
Price: $61.50, Change: $+3.68, Percent Change: +6.36%